Inbinding web-site of AT with GAGs on cell surface.P116 Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for serious sepsis in hospitalised patientsR Launois*, L Riou Franca*, B Guidet, P Aegerter, X Huet? P Meshaka? P Pinton?*REES France, R eau d’Evaluation en Economie de la Sant? 28 rue d’Assas, 75006 Paris, France; H ital Saint Antoine, 184 rue du fb Saint Antoine, 75012 Paris, France; Biostatistique et Informatique m icale, H ital Ambroise Par? 9 avenue Charles de Gaulle, 92100 Boulogne, France; �Laboratoire Lilly France, 203 bureau de la colline, 92213 St Cloud, France Introduction: Drotrecogin alfa (activated) substantially reduced severe sepsis (SevSep) mortality at 28 days [1]. In line with the French budget environment, it really is mandatory to evaluate its cost effectiveness ratio on a pragmatic basis. Procedures: All SevSep sufferers in the Cub-R database (1997?999 CL13900 dihydrochloride biological activity period) defined as outlined by PROWESS [1] and with a hospital length of remain (LOS) 24 hours (n = ten,459) have been integrated. The baseline patients’ traits are equivalent to these of your PROWESS criteria study: age (61 years vs 60 years), < 60 years (42 vs 44 ), and number of organ failure (2.1 vs 2.4). Key patient data recorded: age, gender, type of admission (medical or surgical), admission mode (direct or transfer), number (1, 2, 3), duration and type of support (respiratory, renal, circulatory) and SAPS II. Stratification according to these criteria and loading of the observed frequencies into a decision-tree for conditional probabilities. Relative risk of death with drotrecogin alfa (activated) estimated according to the observed classification into 11 n GHM [2] groups (28 days survival represented by the parametric function of Weibull). SevSep impact on long-term mortality estimatedAvailable online http://ccforum.com/supplements/6/Sby the McCabe score with three hypotheses for life expectancy (LE): unique LE of 5 years, McCabe > 0 (2 years of survival), McCabe = 0 (four years LE reduction or half LE reduction versus entire population). Fees estimated by subgroups and by a linear equation (nursing workload, LOS, SAPS II, living or dead status). Calculation of a differential price effectiveness ratio (drotrecogin alpha (activated) price: 7836.95 for four days remedy along with a imply patient’s weight of 70 kg) and evaluation of Monte Carlo’s type. Results: The anticipated cost within the model of a SevSep patient treated by normal care is 26,983.3 FF96 vs 26,373.6 FF96 observed from Cub-R . The expected cost predicted within the model of a SevSep patient treated by drotrecogin alfa (activated) is 34,605.90 FF96. The survivors LE as outlined by the above hypotheses are 5.0, ten.6, and six.9 years. Corresponding effective-ness differences PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/20724452 in favor of drotrecogin alfa (activated) are 0.33, 0.63, and 0.41 years. The price per extra year of life saved amounts of 18,446.three FF96 such as all degrees of severity and co-morbidity. The sensitivity analysis model shows that with an expected threshold of 53,357.1 FF96, 96.3 from the bootstrap samples are cost-effective. Conclusion: The predicted price effectiveness ratio of drotrecogin alfa (activated) in adult SevSep sufferers is much reduce than the international range regarded as acceptable (53,357.ten ). Drotrecogin alfa (activated) is cost-effective when like individuals with all degrees of co morbidity. The results of these measurements, demographic data, mortality and incidence of acute respiratory distress syndrome (ARDS), MO.